{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T11:44:26Z","timestamp":1789731866949,"version":"4.0.1"},"reference-count":47,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T00:00:00Z","timestamp":1730851200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","award":["2022- 01098"],"award-info":[{"award-number":["2022- 01098"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010767","name":"Innovative Medicines Initiative","doi-asserted-by":"publisher","award":["821528"],"award-info":[{"award-number":["821528"]}],"id":[{"id":"10.13039\/501100010767","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Chemotherapy-induced peripheral neuropathy (CIPN) is a dose-limiting adverse event observed in patients receiving paclitaxel, associated with initial pathological changes in the peripheral nervous system, i.e., distal nerves and dorsal root ganglia (DRG). The prevalence of CIPN in patients receiving paclitaxel formulated i) in polyethylated castor oil with ethanol (CreEL-PTX), ii) as albumin-bound (nab-PTX), and iii) in XR17 micelles (micellar-PTX), is unexpectedly varying. We hypothesize that the discrepancy in CIPN prevalence could be governed by differences in the extent of paclitaxel distribution across blood-to-tissue barriers at the CIPN-sites, caused by the specific formulation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The recently developed Combinatory Mapping Approach for CIPN was used to determine the unbound tissue-to-plasma concentration ratio K<jats:sub>p,uu,tissue<\/jats:sub>, after a 4-h infusion of 4\u00a0mg\/kg CreEL-PTX, 4\u00a0mg\/kg nab-PTX or 1\u00a0mg\/kg micellar-PTX in male and female Sprague Dawley rats. K<jats:sub>p,uu,tissue<\/jats:sub> was determined in conventional (DRG, sciatic nerve) and non-conventional (brain, spinal cord, skeletal muscle) CIPN-sites.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Based on our data, the Cremophor-free paclitaxel formulations were associated with a higher distribution of paclitaxel to CIPN-sites than CreEL-PTX, e.g., K<jats:sub>p,uu,DRG<\/jats:sub> of 0.70 and 0.60 for nab-PTX and micellar-PTX, respectively, in comparison to 0.27 for CreEL-PTX (<jats:italic>p<\/jats:italic> &amp;lt; 0.01). In addition, the fraction of unbound paclitaxel in plasma was on average 1.6-fold higher in nab- and micellar PTX arms and equal to 0.061 and 0.065, respectively, compared to 0.039 for the CreEL-PTX treatment arm (<jats:italic>p<\/jats:italic> &amp;lt; 0.0001).<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>In the case of similar unbound paclitaxel concentration in the plasma of patients and assumed species-independent extent of paclitaxel transport across the barriers, nab- and micellar-PTX formulations can lead to higher paclitaxel exposure at CIPN-sites in comparison to CreEL-PTX.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2024.1486686","type":"journal-article","created":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T05:06:01Z","timestamp":1730869561000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":13,"title":["Formulation-dependent differences in paclitaxel distribution to anatomical sites relevant to chemotherapy-induced peripheral neuropathy"],"prefix":"10.3389","volume":"15","author":[{"given":"Milda","family":"Girdenyt\u0117","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aghavni","family":"Ginosyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margareta","family":"Hammarlund-Udenaes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irena","family":"Loryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,11,6]]},"reference":[{"key":"B1","first-page":"1286","article-title":"Dexamethasone induction of taxol metabolism in the rat","volume":"23","author":"Anderson","year":"1995","journal-title":"Drug Metab. Dispos."},{"key":"B2","doi-asserted-by":"publisher","first-page":"115535","DOI":"10.1016\/j.biopha.2023.115535","article-title":"Neurofilament light chain in plasma as a sensitive diagnostic biomarker of peripheral neurotoxicity: in vivo mouse studies with oxaliplatin and paclitaxel - NeuroDeRisk project","volume":"167","author":"Balayssac","year":"2023","journal-title":"Biomed. Pharmacother. = Biomedecine Pharmacother."},{"key":"B3","doi-asserted-by":"publisher","first-page":"102922","DOI":"10.1016\/j.esmoop.2024.102922","article-title":"Management of infusion-related reactions in cancer therapy: strategies and challenges","volume":"9","author":"Barroso","year":"2024","journal-title":"ESMO Open"},{"key":"B4","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1016\/j.clml.2020.06.022","article-title":"Comparative safety, bioavailability, and pharmacokinetics of oral dexamethasone, 4-mg and 20-mg tablets, in healthy volunteers under fasting and fed conditions: a randomized open-label, 3-way crossover study","volume":"20","author":"Bashir","year":"2020","journal-title":"Clin. Lymphoma, Myeloma Leuk."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1007\/s12325-019-00909-6","article-title":"Maximum tolerated dose and pharmacokinetics of paclitaxel micellar in patients with recurrent malignant solid tumours: a dose-escalation study","volume":"36","author":"Borg\u00e5","year":"","journal-title":"Adv. Ther."},{"key":"B6","doi-asserted-by":"publisher","first-page":"2825","DOI":"10.1007\/s12325-019-01058-6","article-title":"Pharmacokinetics of total and unbound paclitaxel after administration of paclitaxel micellar or nab-paclitaxel: an open, randomized, cross-over, explorative study in breast cancer patients","volume":"36","author":"Borg\u00e5","year":"","journal-title":"Adv. Ther."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1093\/annonc\/mdw260","article-title":"Paclitaxel plus bevacizumab or paclitaxel as first-line treatment for HER2-negative metastatic breast cancer in a multicenter national observational study","volume":"27","author":"Delaloge","year":"2016","journal-title":"Ann. Oncol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1002\/jps.23013","article-title":"Impact of recovery on fraction unbound using equilibrium dialysis","volume":"101","author":"Di","year":"2012","journal-title":"J. Pharm. Sci."},{"key":"B9","doi-asserted-by":"publisher","first-page":"5627","DOI":"10.1007\/s00520-022-06891-0","article-title":"Pre-medication protocols for the prevention of paclitaxel-induced infusion related reactions: a systematic review and meta-analysis","volume":"30","author":"Dubinsky","year":"2022","journal-title":"Support Care Cancer"},{"key":"B10","volume-title":"ICH guidelines","year":"2022"},{"key":"B11","volume-title":"Public statement on apealea: withdrawal of the marketing authorisation in the European union","year":"2024"},{"key":"B12","volume-title":"M10 bioanalytical method validation and study sample analysis","year":"2022"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1172\/JCI15451","article-title":"Transport of paclitaxel (Taxol) across the blood-brain barrier in vitro and in vivo","volume":"110","author":"Fellner","year":"2002","journal-title":"J. Clin. Invest."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1016\/s0959-8049(01)00171-x","article-title":"Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation","volume":"37","author":"Gelderblom","year":"2001","journal-title":"Eur. J. Cancer (Oxford, Engl. 1990)"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1007\/s11095-007-9502-2","article-title":"On the rate and extent of drug delivery to the brain","volume":"25","author":"Hammarlund-Udenaes","year":"2008","journal-title":"Pharm. Res."},{"key":"B16","doi-asserted-by":"publisher","first-page":"4065","DOI":"10.1200\/JCO.2001.19.20.4065","article-title":"Mechanism-based pharmacokinetic model for paclitaxel","volume":"19","author":"Henningsson","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s12987-024-00519-7","article-title":"Analysis of the contributing role of drug transport across biological barriers in the development and treatment of chemotherapy-induced peripheral neuropathy","volume":"21","author":"Hu","year":"2024","journal-title":"Fluids Barriers CNS"},{"key":"B18","doi-asserted-by":"publisher","first-page":"66","DOI":"10.4097\/kjae.2012.62.1.66","article-title":"Gender differences in paclitaxel-induced neuropathic pain behavior and analgesic response in rats","volume":"62","author":"Hwang","year":"2012","journal-title":"Korean J. Anesthesiol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1002\/bdd.325","article-title":"Influence of nonspecific brain and plasma binding on CNS exposure: implications for rational drug discovery","volume":"23","author":"Kalvass","year":"2002","journal-title":"Biopharm. Drug Dispos."},{"key":"B20","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1093\/annonc\/mdx011","article-title":"Fifth ovarian cancer consensus conference of the gynecologic cancer InterGroup: first-line interventions","volume":"28","author":"Karam","year":"2017","journal-title":"Ann. Oncol."},{"key":"B21","first-page":"1220","article-title":"Pharmacokinetic models for the saturable distribution of paclitaxel","volume":"27","author":"Karlsson","year":"1999","journal-title":"Drug Metab. Dispos."},{"key":"B22","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1211\/0022357055966","article-title":"Transport mechanism and substrate specificity of human organic anion transporter 2 (hOat2 [SLC22A7])","volume":"57","author":"Kobayashi","year":"2005","journal-title":"J. Pharm. Pharmacol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1172\/JCI96160","article-title":"OATP1B2 deficiency protects against paclitaxel-induced neurotoxicity","volume":"128","author":"Leblanc","year":"2018","journal-title":"J. Clin. Invest."},{"key":"B24","doi-asserted-by":"publisher","first-page":"4505","DOI":"10.1021\/acs.molpharmaceut.8b00527","article-title":"Different nanoformulations alter the tissue distribution of paclitaxel, which aligns with reported distinct efficacy and safety profiles","volume":"15","author":"Li","year":"2018","journal-title":"Mol. Pharm."},{"key":"B25","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/s12885-021-07831-7","article-title":"Comparison between nab-paclitaxel and solvent-based taxanes as neoadjuvant therapy in breast cancer: a systematic review and meta-analysis","volume":"21","author":"Liu","year":"2021","journal-title":"BMC Cancer"},{"key":"B26","doi-asserted-by":"publisher","first-page":"4362","DOI":"10.1021\/acs.molpharmaceut.7b00480","article-title":"Quantitative assessment of drug delivery to tissues and association with phospholipidosis: a case study with two structurally related diamines in development","volume":"14","author":"Loryan","year":"2017","journal-title":"Mol. Pharm."},{"key":"B27","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.1007\/s11095-014-1319-1","article-title":"Mechanistic understanding of brain drug disposition to optimize the selection of potential neurotherapeutics in drug discovery","volume":"31","author":"Loryan","year":"2014","journal-title":"Pharm. Res."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.7150\/thno.40908","article-title":"Investigating the effects of dexamethasone on blood-brain barrier permeability and inflammatory response following focused ultrasound and microbubble exposure","volume":"10","author":"McMahon","year":"2020","journal-title":"Theranostics"},{"key":"B29","doi-asserted-by":"publisher","first-page":"4843","DOI":"10.1158\/1078-0432.CCR-05-0298","article-title":"Association of Paclitaxel pharmacokinetics with the development of peripheral neuropathy in patients with advanced cancer","volume":"11","author":"Mielke","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"B30","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1177\/0023677215575863","article-title":"Gender differences in a mouse model of chemotherapy-induced neuropathic pain","volume":"50","author":"Naji-Esfahani","year":"2016","journal-title":"Lab. Anim."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.2147\/IJN.S114356","article-title":"An in vivo mechanism for the reduced peripheral neurotoxicity of NK105: a paclitaxel-incorporating polymeric micellar nanoparticle formulation","volume":"12","author":"Nakamura","year":"2017","journal-title":"Int. J. Nanomedicine"},{"key":"B32","doi-asserted-by":"publisher","first-page":"3137","DOI":"10.1158\/0008-5472.CAN-13-3634","article-title":"Influence of drug formulation on OATP1B-mediated transport of paclitaxel","volume":"74","author":"Nieuweboer","year":"2014","journal-title":"Cancer Res."},{"key":"B33","doi-asserted-by":"publisher","first-page":"693133","DOI":"10.3389\/fmolb.2021.693133","article-title":"Review of the role of the brain in chemotherapy-induced peripheral neuropathy","volume":"8","author":"Omran","year":"2021","journal-title":"Front. Mol. Biosci."},{"key":"B34","doi-asserted-by":"publisher","first-page":"e32866","DOI":"10.1097\/MD.0000000000032866","article-title":"Weekly paclitaxel treatment in the first-line therapy of classic Kaposi sarcoma: a real-life study","volume":"102","author":"Paksoy","year":"2023","journal-title":"Medicine"},{"key":"B35","doi-asserted-by":"publisher","first-page":"933","DOI":"10.4161\/cbt.5.8.2875","article-title":"Dexamethasone decreases xenograft response to Paclitaxel through inhibition of tumor cell apoptosis","volume":"5","author":"Pang","year":"2006","journal-title":"Cancer Biol. Ther."},{"key":"B36","doi-asserted-by":"publisher","first-page":"e3000410","DOI":"10.1371\/journal.pbio.3000410","article-title":"The ARRIVE guidelines 2.0: updated guidelines for reporting animal research","volume":"18","author":"Percie du Sert","year":"2020","journal-title":"PLoS Biol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.brainres.2007.06.066","article-title":"An evolving cellular pathology occurs in dorsal root ganglia, peripheral nerve and spinal cord following intravenous administration of paclitaxel in the rat","volume":"1168","author":"Peters","year":"2007","journal-title":"Brain Res."},{"key":"B38","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1002\/bdd.435","article-title":"Comparison of dexamethasone pharmacokinetics in female rats after intravenous and intramuscular administration","volume":"26","author":"Samtani","year":"2005","journal-title":"Biopharm. Drug Dispos."},{"key":"B39","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1016\/j.pain.2014.09.020","article-title":"Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis","volume":"155","author":"Seretny","year":"2014","journal-title":"Pain"},{"key":"B40","doi-asserted-by":"publisher","first-page":"4136","DOI":"10.1158\/1078-0432.CCR-04-2291","article-title":"Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in cremophor (taxol)","volume":"11","author":"Sparreboom","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1124\/jpet.105.092916","article-title":"Improving the in vitro prediction of in vivo central nervous system penetration: integrating permeability, P-glycoprotein efflux, and free fractions in blood and brain","volume":"316","author":"Summerfield","year":"2006","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B42","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s11095-022-03172-7","article-title":"Free drug theory - No longer just a hypothesis?","volume":"39","author":"Summerfield","year":"2022","journal-title":"Pharm. Res."},{"key":"B43","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.biopha.2011.04.031","article-title":"Expression of organic anion-transporting polypeptides 1B1 and 1B3 in ovarian cancer cells: relevance for paclitaxel transport","volume":"65","author":"Svoboda","year":"2011","journal-title":"Biomed. Pharmacother."},{"key":"B44","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1080\/21691401.2018.1552595","article-title":"Efficacy and safety of nanoparticle albumin-bound paclitaxel in non-small cell lung cancer: a systematic review and meta-analysis","volume":"47","author":"Tan","year":"2019","journal-title":"Artif. Cells, Nanomedicine, Biotechnol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.ygyno.2019.11.034","article-title":"A randomized phase III trial in patients with recurrent platinum sensitive ovarian cancer comparing efficacy and safety of paclitaxel micellar and Cremophor EL-paclitaxel","volume":"156","author":"Vergote","year":"2020","journal-title":"Gynecol. Oncol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"750507","DOI":"10.3389\/fphar.2022.750507","article-title":"Mechanisms of chemotherapy-induced neurotoxicity","volume":"13","author":"Was","year":"2022","journal-title":"Front. Pharmacol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"3332","DOI":"10.1158\/0008-5472.CAN-15-2525","article-title":"Sustained accumulation of microtubule-binding chemotherapy drugs in the peripheral nervous system: correlations with time course and neurotoxic severity","volume":"76","author":"Wozniak","year":"2016","journal-title":"Cancer Res."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1486686\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T05:06:05Z","timestamp":1730869565000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1486686\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,6]]},"references-count":47,"alternative-id":["10.3389\/fphar.2024.1486686"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1486686","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,6]]},"article-number":"1486686"}}